---
title: IL-18-secreting multi-antigen targeting CAR T-cells eliminate antigen-low myeloma
  in an immunocompetent mouse model
date: '2024-04-05'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38579288/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240406181030&v=2.18.0.post9+e462414
source: Blood
description: Multiple myeloma is a plasma cell malignancy that is currently incurable
  with conventional therapies. Following the success of CD19-targeted chimeric antigen
  receptor (CAR) T-cells in leukemia and lymphoma, CAR T-cells targeting B-cell maturation
  antigen (BCMA) more recently demonstrated impressive activity in relapsed and refractory
  myeloma patients. However, BCMA-directed therapy can fail due to low expression
  of BCMA on myeloma cells, suggesting that novel approaches to better ...
disable_comments: true
---
Multiple myeloma is a plasma cell malignancy that is currently incurable with conventional therapies. Following the success of CD19-targeted chimeric antigen receptor (CAR) T-cells in leukemia and lymphoma, CAR T-cells targeting B-cell maturation antigen (BCMA) more recently demonstrated impressive activity in relapsed and refractory myeloma patients. However, BCMA-directed therapy can fail due to low expression of BCMA on myeloma cells, suggesting that novel approaches to better ...